Summary Even though many studies suggest that proteoglycans with their structurally determinative polysaccharide chains, the glycosaminoglycans (GAGs), are important mediators of cellular interactions, little is known about expression and possible functions of these macromolecules expressed by tumour cells during the transition from low to highly metastatic behaviour. Therefore, we investigated the cellular expression and secretion of GAGs in a syngeneic tumour system of DBA/2 mice consisting of a methylcholanthrene-induced low metastatic T lymphoma (Eb), its highly metastatic spontaneous variant (ESb), and a low metastatic derivative of ESb (ESb-MP), selected by its adherent growth properties. The [35S]-sulphate-labelled GAGs were isolated from in vitro cultivated cells and further characterized by separation on Sepharose CL 6B, on Mono-Q ion exchange chromatography, and alkali-and enzymatic digestion. In contrast to Eb-cells which produce chondroitin/dermatan sulphate (CS/DS) and heparan sulphate (HS) (cellular extract: CS/DS 67%, HS 33%; culture medium: CS/DS 61%, HS 39%) ESb-and ESb-MP-cells only express and secrete CS/DS. For ESb cells the CS portions consisted of 42% chondroitin-4-sulphate (CS-4) and 58% chondroitin-6-sulphate (CS-6), for ESb-MP cells of 23% CS-4 and 77% CS-6, for Eb cells of 16% CS-4 and 84% CS-6. The cell surface GAGs of the adherent variant ESb-MP contained a significantly higher portion of DS (65%) compared to ESb cells (25%). GAGs of all tumour cell lines studied had a mol. wt ranging from 35-40kD compared to GAG molecular weight standards. Ion exchange chromatography indicated that differences in charge density between GAGs of these cell lines were minimal. These findings suggest that the different biological behaviour of the cell lines cannot be attributed to altered size and charge density of their GAG chains. However, highly metastatic ESb-cells secreted significantly more GAG than low metastatic Eb-and ESb-MP-cells. The possible consequences of the enhanced secretion of CS/DS by ESb-cells are discussed in terms of the postulated role of CS/DS in cellular adhesion, growth regulation and interactions with the immune system. GAGs, the highly anionic sulphated polysaccharide chains of proteoglycans, have been associated with the regulation of cellular interactions, such as cell-cell recognition (Landner et al., 1982) , cell-substrate adhesion (Cole et al., 1985; Stamatoglou & Keller, 1983) , growth control (Fritze et al., 1985) and masking of cell surface receptors (Fransson et al., 1984) . Their ubiquitous expression on the cell surface and in peri-and extracellular spaces suggest that they might play a role in neoplasia and tumour progression (for review see lozzo, 1985). From the data available at the moment it seems that there is not one alteration of proteoglycan expression which is common to all histologically different tumours but rather that each tumour class bears its own characteristic deviations of proteoglycans compared to its normal equivalent.
GAGs, the highly anionic sulphated polysaccharide chains of proteoglycans, have been associated with the regulation of cellular interactions, such as cell-cell recognition (Landner et al., 1982) , cell-substrate adhesion (Cole et al., 1985; Stamatoglou & Keller, 1983) , growth control (Fritze et al., 1985) and masking of cell surface receptors (Fransson et al., 1984) . Their ubiquitous expression on the cell surface and in peri-and extracellular spaces suggest that they might play a role in neoplasia and tumour progression (for review see lozzo, 1985) . From the data available at the moment it seems that there is not one alteration of proteoglycan expression which is common to all histologically different tumours but rather that each tumour class bears its own characteristic deviations of proteoglycans compared to its normal equivalent.
Surprisingly little is known about alterations of expression and secretion of tumour cell proteoglycans/GAGs during the transition of low to highly metastatic capacity. Theoretically, these macromolecules could be involved in several steps of the metastatic cascade: (1) The attachment of tumour cells to the basement membranes of blood vessels and host tissue borders could be influenced by altered expression of proteoglycans, (2) secreted proteoglycans of tumour cells could impair the growth of vascular smooth muscle cells thus facilitating the extravasation process, (3) proteoglycans/ GAGs secreted by tumour cells could modulate functions of immune cells and serum components during tumour cell transportation in the blood circulation. Indications for these postulated functions of GAGs have been obtained already. For instance, a high binding capacity of heparan sulphate to fibronectin and collagen, important components of basement membranes, has been described (Laterra et al., 1983; Spiro & Parthasarathy, 1982) . Furthermore, an antiproliferative effect of heparan sulphate on aortic smooth muscle cells has been reported (Fritze et al., 1985) , GAGs may influence the Correspondence: R. Schwartz-Albiez. Received 10 July, 1987; and in revised from 18 January, 1988. regulation of haemopoiesis (Spooncer et al., 1983) and finally, chondroitin sulphate in human serum is able to bind Clq, reducing the complement-activating properties of this molecule (Silvestri et al., 1981) .
Since there are no data available of the proteoglycan/ GAG profiles of tumour cells differing in their metastatic behaviour, we now analyzed expression and secretion of the GAGs of three related mouse tumour cell lines, a low metastatic T lymphoma (Eb), its highly metastatic variant (ESb) and a low metastatic derivative of ESb (ESb-MP) selected for its adherent growth properties. These tumour lines have been extensively investigated concerning their invasive capacity (Schirrmacher et al., 1979b) , their immunogenicity and tumour-associated transplantation antigens (Schirrmacher et al., 1979a) and their differentiation antigens (Altevogt et al., 1982) . The glycoproteins and glycolipids of cell lines Eb and ESb have been described in two preceding studies (Schwartz et al., 1984; Schwartz et al., 1985) . In the present work, we demonstrate that GAGs from highly metastatic ESb cells are essentially different compared to those from low metastatic Eb cells. Heparan sulphate, which is found on most mammalian cells, is present on Eb-but not on ESb-cells. There is also some variation in the GAG pattern between cell line ESb and its low metastatic, adherent derivative ESb-MP. However, secretion of GAGs seems to be enhanced in the highly metastatic ESb cell line.
We assume, also in view of our findings for glycoprotein and glycolipid changes in this tumour system, that the process towards increasing metastatic capacity coincides with complex alterations in all cell surface expressed glycoconjugates
Materials and methods

Materials
The following materials were used in this study: [35S]-sulfuric acid (carrier free) from New England Nuclear (Boston, MA, USA); [3H]-glucosamine from Amersham and Buchler (Braunschweig, FRG); Bio-Gel P60 (100-200 mesh) from Bio-Rad (Richmond, CA, USA); Sepharose CL-6B, Sephadex G-50 and G-25 and a Mono Q HR 5/5 column from Pharmacia (Uppsala, Sweden); Chondroitinase ABC and AC from Sigma (St Louis, MO, USA), Heparinase and Heparitinase from Seikagaku (Tokyo, Japan); Hyaluronate lyase (prepared from Streptomyces hyaluronilyticus) from Calbiochem (San Diego, CA, USA); Pronase P from Serva (Heidelberg, FRG). GAG molecular weight standards were from a preparation, described by Stuhlsatz et al., 1981 , and were a generous gift from Dr Stuhlsatz (Aachen, FRG).
Cell lines and culture conditions The origin, history and characteristics of the parental tumour line L5 178 YE (= Eb) and its variant L5178 YES (=ESb) have been described elsewhere (Schirrmacher et al., 1979a,b) In addition, a low metastatic variant of ESb, ESb-MP, was used which was selected from ESb cultures by its plastic-adherent growth characteristic in vitro (Benke et al., 1988; Fogel et al., 1983) . Eb and ESb-cells are distinguished from each other by their specific expression of differentiation antigens (Altevogt et al., 1982) , tumour-associated transplantation antigens (TATA) (Schirrmacher et al., 1979a) and cell surface glycoconjugates (Schwartz et al., 1984 whereas the variant ESb-MP is more closely related to ESb. Both cell types express identical differentiation antigens and TATA (Fogel et al., 1983) . All tumour cell lines were cultivated in RPMI 1640 medium (Gibco Biocult, Glasgow, Scotland) containing 10% foetal calf serum (Gibco) and 2mM glutamine. In the case of ESbcells additionally 5 x 10 -5M 2-mercaptoethanol was added. Cell lines Eb and ESb grow in suspension, the adhesive ESb-MP-cells were brought into suspension by short treatment with a 0.2% EDTA solution in PBS. All cell lines were routinely screened for absence of mycoplasms according to Kucherlapati et al. (1975 The adherent ESb-MP cells were incubated with [35S]_ sulphuric acid as described above, washed 10 times with icecold RPMI-medium, detached by scrapping off with a rubber policeman. To remove remaining adherent cells, the culture flasks were further incubated with 0.25% (w/v) EDTA. Both suspensions were pooled and cells were processed as described above. The material still remaining on the culture flask bottom was dissolved in 7 M urea, 0.1 M Tris/HCl, 2% (w/v) SDS pH 7.2 and desalted on BioGel P60 as described below. This treatment should release all extracellular matrix (ECM) material according to Griesmacher et al., 1987; Keller et al., 1987 . For fl-elimination, lyophilized culture media and the 10,000g supernatants from the labelled cells were adjusted to 0.5 M NaOH with 10 M NaOH, incubated at 40 C for 12 h and chromatographed on Bio-Gel P60 (60x 1.4cm) in 0.5MNH4HCO3, 1 mM EDTA. Fractions of 2 ml were collected at 15 mlh 1 and analyzed for radioactivity. Void volume fractions were pooled as indicated in Figure 1 and lyophilized.
Characterization of isolated GAG The lyophilized extracts both of cells and culture media were resuspended in 2 ml of 50mM Tris/HCl, pH 7.5 and subjected with and without proper specific enzymatic treatment both to gel filtration on Sepharose CL 6B and to ion exchange chromatography on Mono Q.
Extracts were treated with i) Chondroitinase ABC or Chondroitinase AC (for both enzymes: 1 unit/80,000 cpm
[35S]-labelled material; or ii) in combined form with Heparitinase/Heparinase (for both enzymes: 0.5 units/80,000cpm
[35S]-labelled material. Enzyme treatment was for 4 h at 37°C
in an incubation buffer containing 0.1 M NaCl, 0.05 M Tris/ HCl, pH7.5 for chondroitinase ABC/AC treatment additionally with 1 mM EDTA and for heparitinase treatment with 2 mm CaCl2. After enzymatic treatment samples were boiled and subjected to chromatography. Gel filtration was performed on a Sepharose CL 6B column (60 x 0.8 cm) and Sephadex G-50 (30 x 0.5 cm) in 0.15 M Tris/HCI buffer, pH 7.5, fractions of 600pl at a flow rate of 9 ml h-1 (Sepharose CL 6B) and fractions of 160 1l at a flow rate of 750y1h-1 (Sephadex G-50) were collected and assayed for radioactivity in a liquid scintillation counter. For estimation of the molecular size we applied GAG molecular standards to CL 6B chromatography. FPLC ion exchange chromatography was done with a Mono Q HR 5/5 column (1 ml volume) using the LCC-500 controller (Pharmacia) in O.IM Tris/HCI, pH 7.5 with a linear gradient from 0 to 1 M NaCl in 45min (flow rate lmlmin-1) as indicated in Figure 4 . Fractions of 1 ml were collected and assayed for radioactivity in a liquid scintillation counter. The CS-4/CS-6 ratio was estimated by HPLC (Bruker, Bremen, FRG) of the unsaturated disaccharides (Greiling et al., 1984) .
Isolation and analysis of GAGs, as described here, was performed three times for all tumour Figure 1 (cell line Eb).
These crude GAG preparations were taken to assess the overall amount of GAGs synthesized and secreted by the cell lines studied. (27, 190) 18 (6,010) 33,200
aCounts and percentage of distribution were calculated from radioactivity eluting in the void volume of the Bio-Gel P60 chromatography Figure 1) . also applied to the Sepharose CL 6B chromatography with and without further enzymatic treatment. In these experiments peaks migrated closer to the V0 of the column than the respective peaks of single GAG chains (data not presented) demonstrating that in all three cell lines studied GAGs were cell-expressed and secreted in proteoglycan form. In a next step [35S]-labelled GAGs were further characterized by their elution profiles on Mono Q ion exchange chromatography (Figure 4) . CS chains of all three tumour lines eluted as a peak between 0.9 and 1.OM NaCl, whereas HS from Eb-cells eluted between 0.8 and 0.9M NaCl. These results indicate that CS of all three cell lines seem to have a similar charge density.
Discussion
The role of proteoglycans/GAGs produced by tumour cells in malignant growth control is still unknown. In a series of papers differences in the production and composition of proteoglycans have been discovered in SV-40 virus -transformed 3T3-cells compared to their non-transformed counterparts (Keller et al., 1980; Underhill & Keller, 1975; Winterbourne & Mora, 1981) .
These authors primarily found a transformation-associated decrease in O-sulphation of cellular expressed proteoheparan sulphates and a decreased self-association ability of HS in transformed cells of this tumour system (Fransson et al., 1981) . It was suggested that these alterations may influence the interaction of HS with other molecules on the cell surface or in the extracellular matrix since it is known that cell-substratum adhesion is partially due to protein-HS interactions (Cole et al., 1985) . In particular, cell surface HS mediates adhesion to fibronectin (Laterra et al., 1983; Stamatoglou & Keller, 1983) . Similar differences in HS synthesis were observed by comparison of normal hepatocytes and hepatoma cells (Robinson et al., 1984) . In order to study the changes of proteoglycan synthesis which may occur during the transition of low to highly metastatic tumour cells, we analyzed the expression and secretion of GAGs of the Eb/ESb-tumour system which consists of cells with different metastatic capacity. Three major observations were made: 1) the cell line ESb and its closely related variant ESb-MP were deficient in producing proteoheparan sulphate in contrast to the parental line Eb, 2) when comparing metastatic behaviour with proteoglycan metabolism the highly metastatic ESb-cells had a significantly higher percentage of secreted proteoglycans than weakly metastatic Eb-and ESb-MP-cells and 3) cell lines ESb and ESb-MP differed markedly in their composition of CS in that cell line ESb-MP contained more and DS compared to cell line ESb.
In particular, secretion of proteochondroitin sulphate of ESb-cells was 4 fold increased compared to Eb-and 2.5 fold to ESb-MP-cells.
Although the exclusive synthesis of proteochondroitin sulphate in ESb-and ESb-MP-cells is an interesting and rarely occurring phenomenon in mammalian cells, only the increased secretion of proteochondroitin sulphate can directly be correlated to the metastatic capacity of the cells. The secretion of proteoglycans was lower in the two weakly metastasizing cell lines of the tumour system which differ otherwise largely in growth behaviour and surface antigen expression (Fogel et al., 1983) . Apparently, differences in charge density of HS as described for the 3T3 cell system are not likely to account for the differences in malignancy of the Eb/ESb system. Concomitantly with the absence of proteoheparan sulphate synthesis ESb-cells produce and secrete a HS degrading endoglycosidase in contrast to Eb-cells. This enzyme has been implicated with the facilitated transgression of the extracellular matrix by metastatic ESb-cells compared to Eb-cells (Vlodavsky et al., 1983) . It seems to be unlikely that the absence of HS in ESb-cells is caused by the simultaneous action of the endoglycosidase. ESb-MP-cells derived directly from ESb-cell cultures also produce only CS but do not produce the HS-degrading endoglycosidase (Hennes et al., in press ). It may be even more likely that both properties -increased secretion of proteochondroitin sulphate and production of the HS-specific endoglycosidaseinfluence in an as yet unresolved fashion the selection of ESb-cells to a favoured metastatic capacity.
It has been reported that colon carcinoma cells produce more proteochondroitin sulphate than normal colon tissue (Iozzo & Wight, 1982) .
The mere production of proteochondroitin sulphate seems to be a peculiar property albeit not a stringently occurring one of cells derived from the haemopoietic system like the tumour cells studied here. For instance, no HS could be isolated from lymphocytes of patients with chronic lymphocytic leukaemia (Capeau et al., 1978) , from lymphocytes of patients with chronic myelogenous leukaemia (Metcalfe et al., 1984) and from cloned granulated lymphocytes with natural killer function and cultured mast cells . Also, proteoglycans of thymic lymphocytes consist largely of proteochondroitin sulphate with only smaller amounts of proteoheparan sulphate. During in vitro stimulation of thymic lymphocytes the proportion of both cellassociated and secreted proteochondroitin sulphate was found to be even increased (Hart, 1982) .
Recpntly, it became more evident that proteoglycans produced by cells of the immune systemlike lymphocytes may not only have a different structure and distribution but also may have different biological functions compared to those of other tissues like epithelium, endothelium or cartilage. Especially, proteochondroitin sulphates seem to be involved in immune processes. For example, a proteochondroitin sulphate localized in granules of natural killer cells is specifically exocytosed when these cells lyse susceptible tumour cell targets (MacDermott et al., 1985) . Furthermore, it has been discovered that a 31 kD glycoprotein termed invariant chain (Ii) which is associated with class II antigens of the major histocompatibility complex (MHC) is also the core protein of an MHC class II-associated proteochondroitin sulphate (Sant et al., 1985) .
In view of these findings it is now tempting to speculate how increased secretion of proteochondroitin sulphate by tumour cells may influence the metastatic process by taking advantage of cell mediated immune mechanisms. For instance, Spooncer et al. (1983) reported that haemopoietically active long-term bone marrow cultures treated with fi-D-xyloside increase their synthesis and secretion of proteochondroitin sulphate but not that of proteoheparan sulphate. This stimulation is matched by a preferential increase in granulocyte-macrophage progenitors (GM-CFC) and in mature granulocytes. We found that the highly metastatic cell line ESb and a non-related highly metastatic mouse BJC-D 6&A F tumour, MDAY-D2, produced constitutively more colony stimulating activity (predominantly granulocyte CSA) than the low metastatic cell line Eb which correlated with an increased tendency to granulocytosis in mice bearing the respective tumours (Schwartz & Monner, 1986) . The increased stimulation of granulocyte production, possibly influenced by secretion of proteochondroitin sulphate may cause disturbances in haemotopoiesis which could give an advantage for the tumnour cells to survive in the host outside the primary tumour.
At this point we have no information about the mechanism of proteoglycan secretion by the tumour cells described here. It may well be that proteoglycans are also included in extracellular plasma membrane vesicles shedded in an increased fashion by ESb compared with Eb cells (Barz et al., 1985) .
When comparing metastatic behaviour and expression of proteoglycans in the Eb/ESb system it has to be considered that cell lines 
